Eve Miller‐Hodges

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

High-Sensitivity Cardiac Troponin and the Risk Stratification of Patients With Renal Impairment Presenting With Suspected Acute Coronary Syndrome

Eve Miller‐Hodges, Atul Anand, Anoop Shah et al. · Circulation · 2017 · 103 citations · Full text

Medicine, Cardiology, Internal Medicine +17

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Long-term outcomes in elderly patients with ANCA-associated vasculitis

Dominic McGovern, S P Williams, Katrina Parsons et al. · Lara D. Veeken · 2019 · 69 citations · Full text

Medicine, Geriatric Medicine, Internal Medicine +16

Activation of podocyte Notch mediates early Wt1 glomerulopathy

Rowan Asfahani, Mona Tahoun, Eve Miller‐Hodges et al. · Kidney International · 2018 · 42 citations · Full text

Medicine, Molecular Biology, Nephrology +17